Literature DB >> 11914897

Nuclear cardiology in the UK: activity and practice 1997.

Elizabeth Prvulovich1, Malcolm J Metcalfe.   

Abstract

A questionnaire was sent to 251 nuclear medicine centres asking for details of nuclear medicine activity, and nuclear cardiology activity and practice in 1997. One hundred and seventy-one (68%) centres replied. Nuclear medicine activity was estimated at 11.8 studies/1,000 population/year, and 9.5% of these studies were within cardiology (1.12 studies/1,000/year). Myocardial perfusion imaging (MPI) studies accounted for 77% and radionuclide ventriculography (RNV) for 22% of all nuclear cardiology. On a national basis this represents activity levels of 0.86 and 0.25 studies/1,000/year for MPI and RNV, respectively. Of the 171 responding centres, 102 (60%) performed MPI studies and 81 (79%) of these reported that activity was increasing. However, MPI activity was unevenly distributed between hospitals. Two centres accounted for 13% of total MPI; others had far lower activity rates, and 51/102 (50%) centres performed less than 200 MPI studies/year. Comparison with previous surveys showed that nuclear medicine activity had almost doubled since 1990 (it was 6.0 studies/1,000 population in 1990, 9.3 studies/1,000 in 1994 and 11.8 studies/1,000 in 1997). Over the same period, nuclear cardiology activity had also risen, the greatest increase being seen for the last 3 years (it was 0.7 studies/1,000 population in 1990, 0.82 studies/1,000 in 1994 and 1.12 studies/1,000 in 1997). Despite these encouraging figures, MPI activity for 1997 remained well below that recommended by the British Cardiac Society in 1994 (2.6 studies/1,000/year) as adequate to serve the needs of patients with cardiac disease in the UK; it was also below the European average activity for the same year (2.2 studies/1,000/year). The anticipated increased workload for nuclear cardiology is encouraging despite the wide and varied practice of nuclear cardiology around the UK. The nuclear medicine community now needs to address the issues that will prevent it keeping up with demand, such as restricted camera time, excessive waiting lists and outdated equipment, but also to standardise acquisition and reporting techniques so that all studies, wherever performed, will be of a uniformly high standard.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914897     DOI: 10.1007/s00259-001-0729-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  7 in total

1.  Activity and practice of nuclear cardiology in the Czech Republic, 2001.

Authors:  Milan Kamínek; Václav Husák; Miroslav Myslivecek; Otto Lang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-14       Impact factor: 9.236

Review 2.  Nuclear cardiology in the UK: do we apply evidence based medicine?

Authors:  S L Rahman; A D Kelion
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 3.  Assessment of prognosis in chronic coronary artery disease.

Authors:  T M Bateman; E Prvulovich
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

4.  Myocardial perfusion scintigraphy in the UK: insights from the British Nuclear Cardiology Society Survey 2000.

Authors:  A D Kelion; C Anagnostopoulos; M Harbinson; S R Underwood; M Metcalfe
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

5.  Myocardial perfusion scintigraphy in Europe 2005: a survey of the European Council on Nuclear Cardiology.

Authors:  S Richard Underwood; Susanna Wiener
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-20       Impact factor: 9.236

6.  Activity of nuclear cardiology in the Czech Republic between 2000 and 2005.

Authors:  Milan Kaminek; Otto Lang; Milena Henzlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

Review 7.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.